Why Is BIOCRYST PHARMACEUTI (BCRX) Stock Up Today?

BCRX stock is up 5.95% to $10.43 in a session marked by a strong intraday rebound and renewed investor interest. The move follows the release of better-than-expected Q2 financial results and the reaffirmation of full-year sales guidance. Analysts have recently adjusted price targets and maintained positive coverage, contributing to the upward momentum.

What Happened

BioCryst Pharma reported Q2 earnings of $0.30 per share, exceeding the $182.514 million revenue estimate with actual sales of $218.250 million. The company also reaffirmed its FY2026 sales guidance of $635 million to $660 million, slightly below the $666.201 million consensus estimate. This performance has reinforced confidence in the commercial strength of its HAE drug Orladeyo, which is driving revenue growth. Recent analyst activity has included RBC Capital and Wedbush maintaining Outperform ratings, albeit with lowered price targets to $13 and $20 respectively. JP Morgan reinstated a Neutral rating with a $12 price target. These developments have combined to spark a positive market reaction.

What The Data Shows

The stock opened at $9.86 and reached a session high of $10.44 at 10:10 AM ET before closing near that level at $10.42. The intraday move reflects a 5.95% increase from the open. Volume has been 0.6 million shares, which is 0.1 times the 3-month average, suggesting limited participation. The stock is trading within its 52-week range of $6.00 to $11.22 and remains unprofitable with a TTM EPS of -1.68 and a net margin of -40.9%. Despite this, revenue is growing at a 68.7% annualized rate. Recent insider transactions include two sales totaling $697,000, with no buys recorded in the last 90 days.

What To Watch

BioCryst Pharma is not scheduled to report earnings in the near term. Investors should monitor the breadth of analyst coverage and any further updates on Orladeyo’s market performance or potential strategic developments.